WESTFORD, Mass., Nov. 6, 2013 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced that Australia's Therapeutic Goods Administration has granted marketing clearance for the PicoSure™ Picosecond Laser, the world's first picosecond laser for the removal of tattoos and benign pigmented lesions. PicoSure was introduced in the United States earlier this year after receiving clearance from the U.S. Food and Drug Administration. The product also is being marketed in the European Union and Canada. "PicoSure continues to be enthusiastically received by physicians and consumers in North America and Europe, and we are excited about the opportunity to market the product to our customers and their patients in Australia, which is a new direct sales territory for the Company," said Cynosure President and CEO Michael Davin. The Company also received approval from the China Food and Drug Administration to market Smartlipo MPX™ LaserBodySculpting™ Workstation, the industry's leading laser-assisted lipolysis system designed to disrupt fat cells and tighten tissue through tissue coagulation. In addition, the PinPointe™ FootLaser™, which Cynosure distributes through an exclusive worldwide agreement with NuvoLase Inc., has been cleared by the Korea Food & Drug Administration for the treatment of Onychomycosis, commonly known as nail fungus. "Further expanding our international product reach is an important part of our long-term growth strategy," Davin said. "International markets generate nearly half of our total laser revenue. Our goal is to continue to enhance our presence in high-growth regions by capitalizing on our outstanding brand reputation, broad distribution capabilities and strong customer relationships. With our innovative laser treatments rapidly gaining in popularity and accessibility around the world, Cynosure is playing an integral role in driving the growth of the global aesthetic market."